Director and 10% owner Carl L. Gordon filed a Form 4 with the SEC on November 10, 2026, disclosing purchases of Electra Therapeutics, Inc. common stock across three trading dates from November 6 through November 10, 2026, through two affiliated investment entities.

Key Highlights

  • Six purchase transactions in Electra Therapeutics common stock were reported by Carl L. Gordon, covering November 6, 9, and 10, 2026.
  • Prices ranged from $7.85 to $8.45 per share across the three trading dates, according to the filing.
  • OPI VII holdings reached 5,255,278 shares following the final reported transaction on November 10, 2026.
  • OrbiMed Genesis holdings reached 2,194,579 shares following the final reported transaction on November 10, 2026.
  • All acquisitions were indirect, held through OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P.
  • Gordon disclaims beneficial ownership of the reported securities except to the extent of any pecuniary interest, as stated in the filing.

Gordon's Purchases Through OrbiMed Entities at Electra Therapeutics

According to the filing, Carl L. Gordon, identified as a Director and 10% Owner of Electra Therapeutics, Inc. (NASDAQ:ETRA), reported six open-market purchases of common stock between November 6 and November 10, 2026. The transactions were executed in two pools: shares held through OrbiMed Private Investments VII, LP ("OPI VII") and shares held through OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis").

On November 6, 2026, the filing reports that OPI VII acquired 9,816 shares at $7.85 per share, bringing its total to 5,230,578 shares, while OrbiMed Genesis acquired 39,600 shares at $7.85 per share, bringing its total to 2,176,579 shares. On November 9, 2026, OPI VII acquired an additional 4,000 shares at $8.24 per share, reaching 5,234,578 shares, and OrbiMed Genesis acquired 16,000 shares at $8.24, reaching 2,192,579 shares. On November 10, 2026, OPI VII acquired 20,700 shares at $8.45 per share, with holdings totaling 5,255,278 shares, and OrbiMed Genesis acquired 2,000 shares at $8.45, with holdings totaling 2,194,579 shares. All transactions carry transaction code "P" (purchase).

The filing notes that OrbiMed Advisors LLC is the managing member of both OrbiMed Capital GP VII LLC (general partner of OPI VII) and OrbiMed Genesis GP LLC (general partner of OrbiMed Genesis), and that OrbiMed Advisors exercises voting and investment power through a management committee comprised of Gordon, W. Carter Neild, and Geoffrey C. Hsu. The filing states that each of Gordon, OrbiMed Advisors, OrbiMed Capital GP VII LLC, and OrbiMed Genesis GP LLC "disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended, except to the extent of its pecuniary interest therein, if any."

What Was Disclosed

Carl L. Gordon, a Director and 10% Owner of Electra Therapeutics, Inc., disclosed six purchases of common stock through two OrbiMed-affiliated funds between November 6 and November 10, 2026, at prices ranging from $7.85 to $8.45 per share, with all beneficial ownership held indirectly.